Excalipoint Therapeutics
PrivateLast Round
Seed
Mar 18, 2026
Total Funding Raised
$109.7M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Excalipoint Therapeutics is a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Excalipoint Therapeutics Comparables
Compare Excalipoint Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kali Therapeutics | 84% | |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 73% | |
| Merck | 73% |
Excalipoint Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 18, 2026 | ||||
| Seed | Aug 1, 2025 |
Excalipoint Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Centurium Capital | Seed |
| Co-Win Ventures | Seed |
| YuanBio Venture Capital | Seed |
| Eisai Innovation | Seed |
| Hony Capital | Seed |
| 5Y Capital | Seed |
| MPC | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 18, 2026
$69M round led by Centurium Capital and HongShan.
Excalipoint Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Excalipoint Therapeutics's valuation, stock price, and market status.
Is Excalipoint Therapeutics a public or private company?
Excalipoint Therapeutics is a private company.
What is the current stock price of Excalipoint Therapeutics?
Excalipoint Therapeutics is a private company, so its shares have no public market price. Caplight tracks Excalipoint Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Excalipoint Therapeutics worth (valuation)?
Valuation information for Excalipoint Therapeutics is not publicly available.
Can I buy Excalipoint Therapeutics stock?
Excalipoint Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Excalipoint Therapeutics's last funding round?
Excalipoint Therapeutics's most recent funding round was Seed on March 18, 2026.
Who are the main investors in Excalipoint Therapeutics?
Key investors in Excalipoint Therapeutics include Centurium Capital, YuanBio Venture Capital, MPC, HongShan Capital Group (HSG), Apricot Capital.
Will Excalipoint Therapeutics IPO soon?
No public IPO plans have been announced for Excalipoint Therapeutics.
How can I track Excalipoint Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Excalipoint Therapeutics's shares on secondary markets.